Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trialArlene O. Siefker‐Radtke, Wei Xue, Nobuaki Matsubara et al.|Annals of Oncology|2023Cited by 82
Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastomaJohnny Duerinck, Anne Rogiers, Frank Van Fraeyenhove et al.|Journal of Neurology|2015Cited by 13
8744 POSTER Extended Use of Adjuvant TMZ in Newly Diagnosed GBM Patients is Safe – Results From the Safety Analysis of the PATSGO TrialF. Hammouch, J.F. Baurain, Tom Boterberg et al.|European Journal of Cancer|2011Cited by 1